Whereas most patients maintained humoral immunity throughout the observation period, we observed reduced cellular immune reactivity as measured by the ancestral-strain-stimulated ELISpot assay in a subset of patients. Half of the individuals (50%; 14/28) maintained cellular immunity three months after the fifth dose, despite acquiring humoral immunity.
19,028 Deaths · 90,262 Hospitalizations · 119,041 Urgent Care · 199,734 Doctor Office Visits · 2,521 Anaphylaxis · 6,356 Bell's Palsy · 2,067 Miscarriages · 9,448 Heart Attacks · 28,602 Myocarditis · 18,388 Permanently Disabled · 9,270 Thrombocytopenia · 15,242 Life Threatening · 36,681 Severe Allergic Reaction · 8,217 Shingles · 5,256 Myocarditis/Pericarditis · 3,710 Thrombocytopenia/Low Platelet ·
·
19,028 Deaths · 90,262 Hospitalizations · 119,041 Urgent Care · 199,734 Doctor Office Visits · 2,521 Anaphylaxis · 6,356 Bell's Palsy · 2,067 Miscarriages · 9,448 Heart Attacks · 28,602 Myocarditis · 18,388 Permanently Disabled · 9,270 Thrombocytopenia · 15,242 Life Threatening · 36,681 Severe Allergic Reaction · 8,217 Shingles · 5,256 Myocarditis/Pericarditis · 3,710 Thrombocytopenia/Low Platelet ·
·